JNNP Milestones in Neurology

In 2020, JNNP reached a significant milestone — 100 continuous years of publishing the innovations, medical breakthroughs and trailblazing studies that have made it the go-to journal across the clinical neurosciences. Unlike other journals that increasingly narrow their focus, JNNP continues to be liberal in its coverage across the clinical neurosciences.

To mark this prodigious century, JNNP asked its readers to choose the most important or transformative development in neurology, neurosurgery or psychiatry in the past 100 years. The winning milestone was announced in Nov 2021 at a virtual celebratory event. Throughout this year we will present these top ten milestones as voted by our readers, focusing on one a month and highlighting the impact that each of these breakthroughs has had in clinical neuroscience since 1920.

We invite you to join us as we commemorate this special anniversary and celebrate a remarkable century of neuroscientific achievement.

JNNP’s Top 10 Milestones

“With discovery, comes further understanding about the triggers to disease, and an appreciation of factors that underly maintenance of brain and mental health. And with such progress, further frontiers that previously seemed impossible, will be realised, from the brain-computer interface through to a regenerating brain”.

– Professor Matthew Kiernan, former Editor-in-Chief of JNNP

Milestone of the month

Parkinson’s Disease: The efficacy of L-Dopa therapy

Presented by: Professor Andrew Lees

L-DOPA, the naturally occurring amino acid precursor of dopamine, has transformed the lives of millions of people with Parkinson’s disease in the fifty years since its introduction. Most patients experience sustained benefit with improved quality of life and some improvement in life expectancy and a total lack of therapeutic response should lead to a reconsideration of the diagnosis. There are no other treatments in neurology that can lead to comparable levels of efficacy in the treatment of motor handicap. A considerable amount of research into developing better symptomatic treatments has returned to trying to develop longer acting oral formulations and alternative modes of delivery of dopa to the brain in order to reduce the unwanted long-term complications of motor fluctuations and hyperkinetic abnormal involuntary movements. For the large majority of people with Parkinson’s disease, irrespective of the age of symptom onset, treatment with L-DOPA combined with a peripheral dopa decarboxylase inhibitor (100/25 mg four times a day) is the initial treatment of choice.


Previous Month’s Milestones

No.1 – Brain Imaging: The development and application of imaging techniques

No.2 – Stroke: Introduction of thrombolysis and endovascular recanalisation therapy

Related Content

Featured Collections


A series of articles published throughout 2020 for JNNP’s centenary

Editorials

Press Releases